At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Observation (other)
- How long the study runs
- Study runs about 70 months (dates as stated)
- About the drug or intervention
- Observation — other: Observation
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 16 Years and over
- Who
- All
- Number of participants
- 60,000
- Started
- 2024-08-01
- Last checked
- 2026-01
Plain English Summary
What is this study?
- • Testing a new treatment for end stage renal disease
- • Clinical study - 60,000 participants
- • Cardiovascular disease is the leading cause of morbidity and mortality among patients with chronic kidney disease (CKD)
Who can take part?
- • Ages 16 Years and over
- • Diagnosed with end stage renal disease
Where?
- • London - Barts Health NHS Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Cardiovascular disease is the leading cause of morbidity and mortality among patients with chronic kidney disease (CKD). Even after adjustment for known cardiovascular risk factors, including diabetes and hypertension, mortality risk progressively increases with worsening CKD. As glomerular filtration rate (GFR) declines the probability of developing coronary artery disease (CAD) increases linearly, and patients with GFR \<60 mL/min/1.73 m2 have 2-3-fold increased CV mortality risk, relative to patients without CKD. Management of CAD is complicated in CKD patients due to the likelihood of comorbid conditions and potential for side effects. Despite their high cardiovascular risk, ACS patients with renal dysfunction are less commonly treated with guideline-based medical therapy and are less frequently referred for coronary revascularisation. This observation, referred to as the "treatment risk paradox," has been well described and may be explained by physicians' concerns regarding possible nonrenal side effects as well as renal toxicities. Furthermore, patients with severe CKD have traditionally been under-represented in most large cardiovascular clinical trials. Therefore, recommendations for both medical and revascularisation of CAD have relied heavily on extrapolation of results from the non-CKD population. This data will add to that literature by assessing the characteristics and outcomes of patients with CAD and CKD. It will also identify and characterise predictors of outcomes, improve risk stratification and diagnostic evaluation.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 16 Years and over
- Who can join: All genders
What the study is looking for
- ✓Both male and female patients ≥16 years of age will be included
- ✓All patients will be reviewed by the Nephrology team a the RLH with kidney disease.
Who cannot take part
- ✗1\. Patients \<16 years will not be included in this study.
See the full criteria
Where Is This Study? (1 UK site)
Barts Health NHS Trust
London EC1A 7BE, United Kingdom
How to Get in Touch
Krishnaraj Rathod, MBBS, PhD
Sponsor contactCONTACT